BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 29929551)

  • 1. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
    Danaher P; Warren S; Lu R; Samayoa J; Sullivan A; Pekker I; Wallden B; Marincola FM; Cesano A
    J Immunother Cancer; 2018 Jun; 6(1):63. PubMed ID: 29929551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
    Higgs EF; Bao R; Hatogai K; Gajewski TF
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
    Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
    J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
    Bao R; Stapor D; Luke JJ
    Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
    Danaher P; Warren S; Ong S; Elliott N; Cesano A; Ferree S
    J Immunother Cancer; 2019 Jan; 7(1):15. PubMed ID: 30665466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic signatures of tumors undergoing T cell attack.
    Gokuldass A; Schina A; Lauss M; Harbst K; Chamberlain CA; Draghi A; Westergaard MCW; Nielsen M; Papp K; Sztupinszki Z; Csabai I; Svane IM; Szallasi Z; Jönsson G; Donia M
    Cancer Immunol Immunother; 2022 Mar; 71(3):553-563. PubMed ID: 34272988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
    Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
    Front Immunol; 2020; 11():558757. PubMed ID: 33329517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
    Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
    J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the role of Frizzled 2 in different cancer types.
    Zhou M; Sun X; Zhu Y
    FEBS Open Bio; 2021 Apr; 11(4):1195-1208. PubMed ID: 33565732
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 20. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
    Dou S; Li R; He N; Zhang M; Jiang W; Ye L; Yang Y; Zhao G; Yang Y; Li J; Chen D; Zhu G
    Front Immunol; 2021; 12():618367. PubMed ID: 34552580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.